Here, we designed and tested a translatable AAV9-based gene therapy approach for CMT1A using an artificial miRNA targeting conserved regions on the human PMP22 and mouse Pmp22 transcripts. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.